An evaluation of RVX-208 for the treatment of atherosclerosis

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Expert Opinion On Drug Safety

Cardiovascular Disease Risk Assessment and Prevention

(2015) Peter Alagona et al.   MEDICAL CLINICS OF NORTH AMERICA

ETC-1002: A future option for lipid disorders?

(2014) Dragana Nikolic et al.   ATHEROSCLEROSIS

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

(2014) Ravi Jahagirdar et al.   ATHEROSCLEROSIS

Treatment of homozygous familial hypercholesterolemia

(2014) Michael France et al.   Clinical Lipidology

Subfractions and Subpopulations of HDL: An Update

(2014) M. Rizzo et al.   CURRENT MEDICINAL CHEMISTRY

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

(2014) Kevin G. McLure et al.   PLoS One

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

(2013) Peter P. Toth et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality

(2013) Marcin Barylski et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208)

(2013) Yuri L. Khmelnitsky et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain

(2013) S. Picaud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

RVX 208

(2013)   Drugs in research & development

ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

(2012) Stephen J. Nicholls et al.   CARDIOVASCULAR DRUGS AND THERAPY

Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

(2012) Aneta Otocka-Kmiecik et al.   PROGRESS IN LIPID RESEARCH

Recombinant HDLMilano exerts greater anti-inflammatory and plaque stabilizing properties than HDLwild-type

(2011) Borja Ibanez et al.   ATHEROSCLEROSIS

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

(2011) Christian Besler et al.   JOURNAL OF CLINICAL INVESTIGATION

Apolipoprotein A-I Therapy

(2011) Michael H. Davidson   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease

(2011) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Targeting endogenous apo A-I—a new approach for raising HDL

(2011) Prediman K. Shah   Nature Reviews Cardiology

Apolipoprotein A-I Mimetic Peptides

(2010) Courtney B. Sherman et al.   Cardiology in Review

RVX-208

(2010) Dana Bailey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE